KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EBIT (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed EBIT for 16 consecutive years, with -$17.5 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 14.2% to -$17.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$86.8 million through Dec 2025, up 22.76% year-over-year, with the annual reading at -$86.8 million for FY2025, 22.76% up from the prior year.
  • EBIT hit -$17.5 million in Q4 2025 for Inovio Pharmaceuticals, up from -$21.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$17.5 million in Q4 2025 to a low of -$105.5 million in Q4 2021.
  • Historically, EBIT has averaged -$45.6 million across 5 years, with a median of -$35.7 million in 2022.
  • Biggest five-year swings in EBIT: tumbled 259.61% in 2021 and later surged 64.43% in 2023.
  • Year by year, EBIT stood at -$105.5 million in 2021, then soared by 46.97% to -$55.9 million in 2022, then surged by 51.04% to -$27.4 million in 2023, then grew by 25.64% to -$20.4 million in 2024, then rose by 14.2% to -$17.5 million in 2025.
  • Business Quant data shows EBIT for INO at -$17.5 million in Q4 2025, -$21.2 million in Q3 2025, and -$23.1 million in Q2 2025.